0.7649 USD
+0.03 (+4.78%)
0.7399 USD
-0.03 (-3.27%)
JAGX gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 191 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of JAGX have multiple concerns. JAGX is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
- JAGX had negative earnings in the past year.
- In the past year JAGX has reported a negative cash flow from operations.
- JAGX had negative earnings in each of the past 5 years.
- In the past 5 years JAGX always reported negative operating cash flow.
1.2 Ratios
- JAGX has a worse Return On Assets (-81.45%) than 74.87% of its industry peers.
- With a Return On Equity value of -716.07%, JAGX is not doing good in the industry: 82.72% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -81.45% | ||
| ROE | -716.07% | ||
| ROIC | N/A |
ROA(3y)-84.47%
ROA(5y)-88.47%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- JAGX has a better Gross Margin (81.92%) than 85.86% of its industry peers.
- In the last couple of years the Gross Margin of JAGX has grown nicely.
- JAGX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 81.92% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y21.72%
GM growth 5Y19.68%
2. Health
2.1 Basic Checks
- JAGX does not have a ROIC to compare to the WACC, probably because it is not profitable.
- The number of shares outstanding for JAGX has been reduced compared to 1 year ago.
- The number of shares outstanding for JAGX has been reduced compared to 5 years ago.
- The debt/assets ratio for JAGX has been reduced compared to a year ago.
2.2 Solvency
- Based on the Altman-Z score of -12.74, we must say that JAGX is in the distress zone and has some risk of bankruptcy.
- Looking at the Altman-Z score, with a value of -12.74, JAGX is doing worse than 78.01% of the companies in the same industry.
- A Debt/Equity ratio of 1.36 is on the high side and indicates that JAGX has dependencies on debt financing.
- JAGX has a worse Debt to Equity ratio (1.36) than 76.44% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.36 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -12.74 |
ROIC/WACCN/A
WACC1.31%
2.3 Liquidity
- JAGX has a Current Ratio of 0.81. This is a bad value and indicates that JAGX is not financially healthy enough and could expect problems in meeting its short term obligations.
- JAGX has a worse Current ratio (0.81) than 88.48% of its industry peers.
- JAGX has a Quick Ratio of 0.81. This is a bad value and indicates that JAGX is not financially healthy enough and could expect problems in meeting its short term obligations.
- JAGX has a worse Quick ratio (0.52) than 89.01% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.81 | ||
| Quick Ratio | 0.52 |
3. Growth
3.1 Past
- The earnings per share for JAGX have decreased strongly by -19.82% in the last year.
- The Revenue has grown by 12.45% in the past year. This is quite good.
- Measured over the past years, JAGX shows a quite strong growth in Revenue. The Revenue has been growing by 15.14% on average per year.
EPS 1Y (TTM)-19.82%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%76.08%
Revenue 1Y (TTM)12.45%
Revenue growth 3Y39.19%
Revenue growth 5Y15.14%
Sales Q2Q%-0.8%
3.2 Future
- JAGX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 40.54% yearly.
- JAGX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 118.46% yearly.
EPS Next Y89.56%
EPS Next 2Y40.54%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year24.03%
Revenue Next 2Y26.98%
Revenue Next 3Y160.53%
Revenue Next 5Y118.46%
3.3 Evolution
- The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
- The Price/Earnings Ratio is negative for JAGX. In the last year negative earnings were reported.
- Also next year JAGX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- JAGX's earnings are expected to grow with 40.54% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y40.54%
EPS Next 3YN/A
5. Dividend
5.1 Amount
- No dividends for JAGX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
JAGUAR HEALTH INC / JAGX FAQ
What is the fundamental rating for JAGX stock?
ChartMill assigns a fundamental rating of 2 / 10 to JAGX.
What is the valuation status of JAGUAR HEALTH INC (JAGX) stock?
ChartMill assigns a valuation rating of 1 / 10 to JAGUAR HEALTH INC (JAGX). This can be considered as Overvalued.
What is the profitability of JAGX stock?
JAGUAR HEALTH INC (JAGX) has a profitability rating of 1 / 10.
How financially healthy is JAGUAR HEALTH INC?
The financial health rating of JAGUAR HEALTH INC (JAGX) is 1 / 10.
What is the earnings growth outlook for JAGUAR HEALTH INC?
The Earnings per Share (EPS) of JAGUAR HEALTH INC (JAGX) is expected to grow by 89.56% in the next year.